Switch theme
Sign up to access all valuation multiples
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company’s technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.
2001
118
LTM Revenue $1.4M
Last FY EBITDA -$20.2M
$45.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pluri has a last 12-month revenue (LTM) of $1.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Pluri achieved revenue of $0.3M and an EBITDA of -$20.2M.
Pluri expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pluri valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$20.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -6204% | XXX | XXX | XXX |
| EBIT | -$18.9M | XXX | -$22.2M | XXX | XXX | XXX |
| EBIT Margin | -1348% | XXX | -6797% | XXX | XXX | XXX |
| Net Profit | -$18.2M | XXX | -$20.9M | XXX | XXX | XXX |
| Net Margin | -1300% | XXX | -6407% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $17.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Pluri's stock price is $5.
Pluri has current market cap of $40.9M, and EV of $45.8M.
See Pluri trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45.8M | $40.9M | XXX | XXX | XXX | XXX | $-2.98 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Pluri has market cap of $40.9M and EV of $45.8M.
Pluri's trades at 55.1x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate Pluri's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pluri has a P/E ratio of -2.2x.
See valuation multiples for Pluri and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40.9M | XXX | $40.9M | XXX | XXX | XXX |
| EV (current) | $45.8M | XXX | $45.8M | XXX | XXX | XXX |
| EV/Revenue | 32.7x | XXX | 55.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -2.4x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | 62.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.2x | XXX | -2.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPluri's last 12 month revenue growth is 112%
Pluri's revenue per employee in the last FY averaged $3K, while opex per employee averaged $0.2M for the same period.
Pluri's rule of 40 is -7703% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pluri's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pluri and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 112% | XXX | 177% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -7703% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $3K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3818% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6896% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pluri acquired XXX companies to date.
Last acquisition by Pluri was XXXXXXXX, XXXXX XXXXX XXXXXX . Pluri acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pluri founded? | Pluri was founded in 2001. |
| Where is Pluri headquartered? | Pluri is headquartered in United States of America. |
| How many employees does Pluri have? | As of today, Pluri has 118 employees. |
| Who is the CEO of Pluri? | Pluri's CEO is Mr. Yaky Yanay. |
| Is Pluri publicy listed? | Yes, Pluri is a public company listed on NAS. |
| What is the stock symbol of Pluri? | Pluri trades under PLUR ticker. |
| When did Pluri go public? | Pluri went public in 1991. |
| Who are competitors of Pluri? | Similar companies to Pluri include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Pluri? | Pluri's current market cap is $40.9M |
| What is the current revenue of Pluri? | Pluri's last 12 months revenue is $1.4M. |
| What is the current revenue growth of Pluri? | Pluri revenue growth (NTM/LTM) is 112%. |
| What is the current EV/Revenue multiple of Pluri? | Current revenue multiple of Pluri is 32.7x. |
| Is Pluri profitable? | Yes, Pluri is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
